CytomX Therapeutics Reports 92% Revenue Decline and $20.7 Million Net Loss in Latest Quarter

CytomX Therapeutics, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated revenues of $1.4 million for the quarter, a stark decline of approximately 92% compared to $18.7 million in the same period last year. For the first half of 2026, revenues totaled $11.7 million, down from $69.6 million in the first half of 2025. The decrease in revenue was primarily attributed to the termination of collaboration agreements with Amgen and Astellas, which resulted in the recognition of all remaining deferred revenue under those agreements in prior periods.

Operating expenses for CytomX also increased, totaling $25.2 million for the second quarter of 2026, compared to $19.9 million in the same quarter of 2025. Research and development expenses rose to $17.6 million from $13.3 million year-over-year, driven by increased manufacturing activities for its lead product candidate, Varseta-M. The company reported a net loss of $20.7 million for the quarter, compared to a loss of $154,000 in the same quarter of the previous year. For the first half of 2026, the net loss was $38.9 million, a significant shift from a net income of $23.4 million in the first half of 2025.

In terms of strategic developments, CytomX has been focusing on advancing its clinical pipeline, particularly its PROBODY therapeutic platform. The company is currently conducting clinical trials for Varseta-M, an investigational antibody-drug conjugate targeting epithelial cell adhesion molecule (EpCAM), and CX-801, a masked version of interferon alpha-2b. The company has initiated a Phase 1 combination study of Varseta-M with bevacizumab and plans to expand its clinical trials to include additional indications. However, the company faces challenges in patient enrollment and the execution of clinical trials, which could impact its development timelines.

CytomX's financial position has improved, with cash, cash equivalents, and short-term investments totaling $330.3 million as of June 30, 2026, compared to $137.1 million at the end of 2025. This increase is largely due to a successful underwritten public offering in March 2026, which raised approximately $234.2 million. The company anticipates that its existing capital resources will be sufficient to fund operations into at least the second half of 2028. However, it acknowledges the need for additional funding to support ongoing development efforts and may seek further collaborations or financing options in the future.

Looking ahead, CytomX remains optimistic about its product candidates and the potential for future collaborations. However, the company cautions that the path to commercialization is fraught with uncertainties, including regulatory approvals, market acceptance, and competition from other biopharmaceutical companies. The company’s ability to successfully navigate these challenges will be critical to its long-term viability and growth in the oncology market.